Filing Flows › Amneal Pharmaceuticals (AMRX) › Q3 2026
Amneal Pharmaceuticals (AMRX) Q3 2026 earnings results (third quarter 2026)
8-K filed Nov 3, 2026
Amneal Pharmaceuticals (AMRX) reported revenue of $863M for the third quarter 2026 (Q3 2026), +10% from a year earlier and +8% from the quarter before. Operating margin was 11.1%, net earnings $12.3M (1.4% of revenue).
Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $863M | +8% | +10% |
| Gross profit | $334M | -0.1% | +22% |
| Operating profit | $95.4M | -26% | +36% |
| Net earnings | $12.3M | -82% | -32% |
| Operating cash flow | $98.3M | — | -17% |
| Free cash flow | $66.5M | — | -37% |
What changed
Revenue was $862.7M in Q3 2026, up 10% year over year and up 8% from the previous quarter.
Gross margin was 38.7%, up 3.8 points from Q3 2025. Operating profit was $95.4M, a 11.1% margin (up 2.1 points year over year). Of the extra revenue versus Q3 2025, 32% reached operating profit, above the 9% margin then. Operating expenses grew 17% against revenue growth of 10%. The fastest-growing cost line was Other operating costs (+1146%). Net earnings were −$7.5M. The effective tax rate was 18.3%.
Operating cash flow was $98.3M (down 17% year over year), 799% of net income including minority interests. Non-cash charges added back $10.5M of share-based compensation. Working capital and other items added $75.5M. Capital expenditures of $31.8M left free cash flow of $66.5M.
Questions
What was Amneal Pharmaceuticals' revenue in the third quarter 2026?
Amneal Pharmaceuticals (AMRX) reported revenue of $863M for the third quarter 2026 (Q3 2026), +10% from a year earlier and +8% from the quarter before.
Was Amneal Pharmaceuticals profitable in the third quarter 2026?
Operating profit was $95.4M (11.1% of revenue) and net earnings $12.3M.